Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

Cristiana Lavazza, Carmelo Carlo-Stella, Arianna Giacomini, Loredana Cleris, Marco Righi, Daniela Sia, Massimo Di Nicola, Michele Magni, Paolo Longoni, Marco Milanesi, Maura Francolini, Annunziata Gloghini, Antonino Carbone, Franca Formelli, Alessandro M. Gianni

Blood (2010) 115 (11): 2231–2240.

https://doi.org/10.1182/blood-2009-08-239632

Published: 2010

Includes: Supplemental data

Journal Articles

Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas

Carmelo Carlo-Stella, MD, Cristiana Lavazza, PhD, Arianna Giacomini, PhD, Loredana Cleris, Daniela Sia, PhD, Paolo Longoni, Marco Milanesi, Michele Magni, MD, Massimo Di Nicola, MD, Annunziata Gloghini, PhD, Antonino Carbone, MD, Marco Righi, MD, Franca Formelli, PhD, Alessandro M. Gianni, MD

Blood (2008) 112 (11): 2605.

https://doi.org/10.1182/blood.V112.11.2605.2605

Published: 2008

Journal Articles

Interferon γ Enhances the Anti-Myeloma Activity of the Fully Human Anti-HLA-DR Monoclonal Antibody 1D09C3.

Carmelo Carlo-Stella, MD, Anna Guidetti, MD, Massimo Di Nicola, MD, Cristiana Lavazza, Loredana Cleris, Paolo Longoni, Marco Milanesi, Michele Magni, MD, Zoltan Nagy, Paolo Corradini, MD, Antonino Carbone, MD, Franca Formelli, Alessandro M. Gianni, MD

Blood (2006) 108 (11): 656.

https://doi.org/10.1182/blood.V108.11.656.656

Published: 2006

Journal Articles

In Vitro and In Vivo Activity of SKI-606, a Novel Abl/Src Inhibitor, Against Imatinib Resistant BCR-ABL+ Neoplastic Cells.

Miriam Puttini, Addolorata M.L. Coluccia, Frank Boschelli, Anna Franceschino, Lucia Tornaghi, Shaheen Ahmed, Sara Redaelli, Rocco Piazza, Vera Magistroni, Federica Andreoni, Leonardo Scapozza, Franca Formelli, Carlo Gambacorti

Blood (2006) 108 (11): 2176.

https://doi.org/10.1182/blood.V108.11.2176.2176

Published: 2006

Journal Articles

In Vitro and In Vivo Anti-Lymphoma Activity of the Anti-HLA-DR Monoclonal Antibody 1D09C3.

Carmelo Carlo-Stella, MD, Massimo Di Nicola, MD, Caterina Turco, MD, Loredana Cleris, Cristiana Lavazza, PhD, Marco Milanesi, Paolo Longoni, Elisabetta Zorzan, PhD, Michele Magni, MD, Massimo Ammirante, PhD, Arturo Leone, MD, Franca Formelli, PhD, Alessandro M. Gianni, MD

Blood (2004) 104 (11): 3285.

https://doi.org/10.1182/blood.V104.11.3285.3285

Published: 2004

Journal Articles

Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.

Carmelo Carlo-Stella, MD, Massimo Di Nicola, MD, Paolo Longoni, Loredana Cleris, Marco Milanesi, Cristiana Lavazza, PhD, Raffaella Milani, MD, Matteo Carrabba, MD, Franca Formelli, PhD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2004) 104 (11): 3460.

https://doi.org/10.1182/blood.V104.11.3460.3460

Published: 2004

Journal Articles

Placental Growth Factor (PlGF) Synergizes with Granulocyte Colony-Stimulating Factor (G-CSF) for the Mobilization of Primitive and Committed Peripheral Blood Progenitor Cells (PBPCs) in Nonhuman Primates.

Carmelo Carlo-Stella, MD, Massimo Di Nicola, MD, Paolo Longoni, Raffaella Milani, MD, Marco Milanesi, Michele Magni, MD, Loredana Cleris, Franca Formelli, PhD, Virgilio Pace, DVM, Francesco Colotta, MD, Alessandro M. Gianni, MD

Blood (2004) 104 (11): 4994.

https://doi.org/10.1182/blood.V104.11.4994.4994

Published: 2004

Journal Articles

Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34 + cells in poor mobilizers

Carmelo Carlo-Stella, Massimo Di Nicola, Raffaella Milani, Anna Guidetti, Michele Magni, Marco Milanesi, Paolo Longoni, Paola Matteucci, Franca Formelli, Fernando Ravagnani, Paolo Corradini, Alessandro M. Gianni

Blood (2004) 103 (9): 3287–3295.

https://doi.org/10.1182/blood-2003-07-2428

Published: 2004

Journal Articles

Bcl-X L down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo

Addolorata Maria Luce Coluccia, Silvia Perego, Loredana Cleris, Rosalind Helen Gunby, Lorena Passoni, Edoardo Marchesi, Franca Formelli, Carlo Gambacorti-Passerini

Blood (2004) 103 (7): 2787–2794.

https://doi.org/10.1182/blood-2003-09-3144

Published: 2004

NARROW

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas

Interferon γ Enhances the Anti-Myeloma Activity of the Fully Human Anti-HLA-DR Monoclonal Antibody 1D09C3.

In Vitro and In Vivo Activity of SKI-606, a Novel Abl/Src Inhibitor, Against Imatinib Resistant BCR-ABL+ Neoplastic Cells.

In Vitro and In Vivo Anti-Lymphoma Activity of the Anti-HLA-DR Monoclonal Antibody 1D09C3.

Primary Plasma Cells Expressing CD52 Are Efficiently Targeted In Vivo by Alemtuzumab.

Placental Growth Factor (PlGF) Synergizes with Granulocyte Colony-Stimulating Factor (G-CSF) for the Mobilization of Primitive and Committed Peripheral Blood Progenitor Cells (PBPCs) in Nonhuman Primates.

Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34 + cells in poor mobilizers

Bcl-X L down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only